Aprepitant (EMEND)

References

• Dando T M, Perry C M. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting Drugs 2004; 64(7)777–94
   Google Scholar
• Endo T, Minami M, Hirafuji M, Ogawa T, Akita K, Nemoto M, et al. Neurochemistry and neuropharmacology of emesis-the role of serotonin. Toxicology Nov 16, 2000; 153(1–3)189–201
   PubMed Web of Science ®Google Scholar
• Hornby P J. Central neurocircuitry associated with emesis. Am J Med 2001; 111(Suppl 8A)106S–112S
   PubMed Web of Science ®Google Scholar
• Gwyn D G, Leslie R A, Hopkins D A. Gastric afferents to the nucleus of the solitary tract in the cat. Neurosci Lett 1979; 14(1)13–7
   Google Scholar
• Ciriello J, Hrycyshyn A W, Calaresu F R. Glossopharyngeal and vagal afferent projection to the brainstem of the cat. J Auton Nerv Sys 1981; 4(1)63–79
   Google Scholar
• Fukuda H, Koga T. The Bötzinger complex as the pattern generator for retching and vomiting in the dog. Neurosci Res 1991; 12(4)471–85
   Google Scholar
• Furukawa N, Fukuda H, Hatano M, Koga T, Shiroshita Y. A neurokinin-1 receptor antagonist reduced hypersalivation and gastric contractility related to emesis in dogs. Am J Physiol 1998; 275(5 Pt 1)G1193–201
   Google Scholar
• Alford S, Schwartz E, Viana di Prisco G. The pharmacology of vertebrate spinal central pattern generators. Neuroscientist 2003; 9(3)217–28
   Google Scholar
• Lang I M. Digestive tract motor correlates of vomiting and nausea. Can J Physiol Pharmacol 1990; 68(2)242–53
   Google Scholar
• Miller A D. Central mechanisms of vomiting. Dig Dis Sci 1999; 44(8 Suppl)39S–43S
   Google Scholar
• Lang I M. Noxious stimulation of emesis. Dig Dis Sci 1999; 44(8 Suppl)58S–63S
   PubMed Web of Science ®Google Scholar
• Mitchelson F. Pharmacological agents affecting emesis. A review (Part I). Drugs 1992; 43(3)295–315
   Google Scholar
• Butler A, Hill J M, Ireland S J, Jordan C C, Tyers M B. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 1988; 94(2)397–412
   Google Scholar
• Round A, Wallis D I. The depolarizing action of 5-hydroxytryptamine on rabbit vagal afferent and sympathetic neurones in vitro and its selective blockade by ICS 205–930. Br J Pharmacol 1986; 88(2)485–94
   Google Scholar
• Ireland S J, Tyers M B. Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol 1987; 90(1)229–38
   Google Scholar
• Marty M, Pouillart P, Scholl S, Droz J P, Azab M, Brion N, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322(12)816–21
   PubMed Web of Science ®Google Scholar
• King G L, Landauer M R. Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret. J Pharmacol Exp Ther 1990; 253(3)1026–33
   Google Scholar
• Kilpatrick G J, Jones B J, Tyers M B. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987; 330(6150)746–8
   Google Scholar
• Kilpatrick G J, Jones B J, Tyers M B. Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 1989; 159(2)157–64
   Google Scholar
• Barnes J M, Barnes N M, Costall B, Naylor I L, Naylor R J, Rudd J A. Topographical distribution of 5-HT3 receptor recognition sites in the ferret brain stem. Naunyn Schmiedebergs Arch Pharmacol 1990; 342(1)17–21
   Google Scholar
• Andrews P L, Davis C J, Bingham S, Davidson H I, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990; 68(2)325–45
   Google Scholar
• Lucot J B. Blockade of 5-hydroxytryptamine3 receptors prevents cisplatin-induced but not motion-or xylazine-induced emesis in the cat. Pharmacol Biochem Behav 1989; 32(1)207–10
   Google Scholar
• Tian Y, Wu L H, Oxender D L, Chung F Z. The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J Biol Chem 1996; 271(34)20250–7
   Google Scholar
• Regoli D, Boudon A, Fauchere J L. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 1994; 46(4)551–99
   PubMed Web of Science ®Google Scholar
• Mantyh P W. Substance P and the inflammatory and immune response. Ann N Y Acad Sci. 1991; 632: 263–71
   Google Scholar
• Patacchini R, Maggi C A. Tachykinin receptors and receptor subtypes. Arch Int Pharmacodyn Ther 1995; 329(1)161–84
   Google Scholar
• Saito R, Takano Y, Kamiya H O. Roles of substance P and NK (1) receptor in the brainstem in the development of emesis. J Pharmacol Sci 2003; 91(2)87–94
   Google Scholar
• Baude A, Shigemoto R. Cellular and subcellular distribution of substance P receptor immunoreactivity in the dorsal vagal complex of the rat and cat: a light and electron microscope study. J Comp Neurol 1998; 402(2)181–96
   Google Scholar
• Watson J W, Gonsalves S F, Fossa A A, McLean S, Seeger T, Obach S, et al. The anti-emetic effects of CP-99, 994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 1995; 115(1)84–94
   PubMed Web of Science ®Google Scholar
• Krowicki Z K, Hornby P J. Substance P in the dorsal motor nucleus of the vagus evokes gastric motor inhibition via neurokinin 1 receptor in rat. J Pharmacol Exp Ther 2000; 293(1)214–21
   Google Scholar
• Fodor M, Pammer C, Gorcs T, Palkovits M. Neuropeptides in the human dorsal vagal complex: An immunohistochemical study. J Chem Neuroanat 1994; 7(3)141–57
   Google Scholar
• Gardner C J, Bountra C, Bunce K T, et al. Antiemetic activity of neurokinin NK1 receptor antagonists is mediated centrally in the ferret. Br J Pharmacol 1994; 112(Suppl)516P–516P, abstract
   Google Scholar
• Andrews P L, Okada F, Woods A J, Hagiwara H, Kakaimoto S, Toyoda M, et al. The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew. Br J Pharmacol 2000; 130(6)1247–54
   Google Scholar
• Ladic L A, Buchan A M. Three-dimensional spatial relationship of neuropeptides and receptors in the rat dorsal vagal complex. Brain Res 1998; 795(1–2)312–24
   Google Scholar
• Manaker S, Zucchi P C. Effects of vagotomy on neurotransmitter receptors in the rat dorsal vagal complex. Neuroscience 1993; 52(2)427–41
   Google Scholar
• Smid S D, Lynn P A, Templeman R, Blackshaw L A. Activation of non-adrenergic non-cholinergic inhibitory pathways by endogenous and exogenous tachykinins in the ferret lower oesophageal sphincter. Neurogastroenterol Motil 1998; 10(2)149–56
   Google Scholar
• Rudd J A, Jordan C C, Naylor R J. The action of the NK1 tachykinin receptor antagonist, CP 99, 994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 1996; 119(5)931–6
   PubMed Web of Science ®Google Scholar
• Tattersall F D, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson D J, et al. The novel NK1 receptor antagonist MK-0869 (L-754, 030) and its water soluble phosphoryl prodrug, L-758, 298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000; 39(4)652–63
   PubMed Web of Science ®Google Scholar
• Tattersall F D, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod A M, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996; 35(8)1121–9
   PubMed Web of Science ®Google Scholar
• Bergstrom M, Hargreaves R J, Burns H D, Goldberg M R, Sciberras D, Reines S A, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 2004; 55(10)1007–12
   PubMed Web of Science ®Google Scholar
• EMEND package insert. 2003
   Google Scholar
• Aprepitant (Emend) for prevention of nausea and vomiting due to cancer chemotherapy. Med Lett Drugs Ther. 2003; 45(1162)62–3
   Google Scholar
• Shadle C R, Lee Y, Majumdar A K, Petty K J, Gargano C, Bradstreet T E, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004; 44(3)215–23
   PubMed Web of Science ®Google Scholar
• Feuring M, Lee Y, Orlowski L H, Michiels N, De Smet M, Majumdar A K, et al. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol 2003; 43(8)912–7
   PubMed Web of Science ®Google Scholar
• Hesketh P J, Gandara D R. Serotonin antagonists: A new class of antiemetic agents. J Natl Cancer Inst 1991; 83(9)613–20
   Google Scholar
• Hesketh P J. Treatment of chemotherapy-induced emesisin the 1990s: Impact of the 5-HT3 receptor antagonists. Support Care Cancer 1994; 2(5)286–92
   Google Scholar
• Hesketh P J, Harvey W H, Harker W G, Beck T M, Ryan T, Bricker L J, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12(3)596–600
   Google Scholar
• Roila F. Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Group for Antiemetic Research. Oncology 1996; 53(Suppl 1)65–72
   Google Scholar
• Frakes L A, Brehm T L, Kosty M P, Miller W E, McMillan R L, Mason J, et al. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem transplant. Bone Marrow Transplant 1997; 20(6)473–8
   Google Scholar
• Campos D, Pereira J R, Reinhardt R, Carracedo C, Poli S, Vogel C, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19(6)1759–67
   PubMed Web of Science ®Google Scholar
• Navari R, Reinhardt R, Gralla R J, Kris M G, Hesketh P J, Khojasteh A, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med 1999; 340(3)190–5
   PubMed Web of Science ®Google Scholar
• Cocquyt V, Van Belle S, Reinhardt R, Decramer M L, O'Brien M, Schellens J H, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37(7)835–42
   PubMed Web of Science ®Google Scholar
• Van Belle S, Lichinitser M R, Navari R, Garin A M, Decramer M L, Riviere A, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758, 298 and MK-869: A randomized controlled trial. Cancer 2002; 94(11)3032–41
   Google Scholar
• Hesketh P J, Grunberg S M, Gralla R J, Warr D G, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21(22)4112–9, Epub 2003 Oct 14.
   PubMed Web of Science ®Google Scholar
• Chawla S P, Grunberg S M, Gralla R J, Hesketh P J, Rittenberg C, Elmer M E, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97(9)2290–300
   PubMed Web of Science ®Google Scholar
• Martin A R, Pearson J D, Cai B, et al. Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis. Qual Life Res 2000; 9: 18
   Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides A D, Julie Ma G, Eldridge K, Hipple A, et al. Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97(12)3090–8
   PubMed Web of Science ®Google Scholar
• McCrea J B, Majumdar A K, Goldberg M R, Iwamoto M, Gargano C, Panebianco D L, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74(1)17–24
   PubMed Web of Science ®Google Scholar
• Hande K, Nygren P, Fedgchin M, Vandyck K, Majumdar A, Panebianco D, et al. An open-label, balanced, 2-period crossover study to investigate the influence of aprepitant on docetaxel pharmacokinetics Abstract 2094. Vanderbilt University, Nashville, TN 2004, Uppsala University Hospital, Uppsala, Sweden; University Hospital Ghent, Belgium. ASCO
   Google Scholar
• Blum R A, Majumdar A, McCrea J, Busillo J, Orlowski L H, Panebianco D, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003, 5: 1407–19
   Google Scholar
• Majumdar A K, McCrea J B, Panebianco D L, Hesney M, Dru J, Constanzer M, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003; 74(2)150–6
   PubMed Web of Science ®Google Scholar
• Warr D G, Eisenberg P, Hesketh P J, Gralla R J, Muss H, Raftopolous H, Gabriel M, Rodgers A, Hustad C M, Skobieranda F. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients. ASCO Meeting Abstracts. J Clin Oncol. Jul 15, 2004; 8007
   Google Scholar
• Kramer M S, Winokur A, Kelsey J, Preskorn S H, Rothschild A J, Snavely D, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29(2)385–92
   PubMedGoogle Scholar
• Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Gallagher S, Charu V. Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy (CT) ASCO Meeting Abstracts. J Clin Oncol. Jul 15, 2004; 8262
   Google Scholar